Thursday, December 1, 2011
Cytokinetics Inc., of South San Francisco, reported data from the first cohort of an ongoing Phase II study of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), showing that the drug was well tolerated when dosed daily as a single agent for two weeks. Those data were presented at the International Symposium on ALS/MND in Sydney, Australia. Cytokinetics recently started the second cohort of the study, which is expected to test the drug in 24 ALS patients who are receiving riluzole. CK-2017357 is a selective fast skeletal muscle troponin complex activator.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.